Latest Sanofi-Aventis Stories
PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(®) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study
Hear from Sanofi Aventis how intelligent Central Statistical Monitoring techniques have been harnessed to improve data quality and oversight.
Parker Waichman LLP has filed a lawsuit on behalf of a man who experienced hemorrhaging, allegedly due to the use of Plavix (clopidogrel).
- Of or relating to good digestion.